Dynorphin A

Dynorphin A is a 17-amino acid endogenous opioid peptide derived from the precursor protein prodynorphin. Discovered in 1979 by Avram Goldstein's laboratory, dynorphin was named for its "dynamic" potency — it was initially reported to be extraordinarily potent at opioid receptors. Dynorphin A acts primarily at kappa-opioid receptors (KOR), distinguishing it from beta-endorphin (which prefers mu receptors) and enkephalins (which prefer delta receptors). This kappa receptor selectivity gives dynorphin a unique and often aversive pharmacological profile.

Unlike the euphoria associated with mu-opioid receptor activation, kappa-opioid receptor activation by dynorphin produces dysphoria, sedation, and aversive emotional states. This has led to the concept that dynorphin functions as an "anti-reward" signal in the brain. In the nucleus accumbens and ventral tegmental area, dynorphin release inhibits dopamine neurotransmission, reducing reward signaling. This anti-reward function is hypothesized to play a role in the development of addiction, where chronic drug use upregulates dynorphin, contributing to negative emotional states during withdrawal.

In pain processing, dynorphin A has a complex and paradoxical role. While it can produce analgesia through kappa receptor activation, elevated dynorphin levels in the spinal cord have been associated with chronic pain states, particularly neuropathic pain. Research has shown that pathologically elevated spinal dynorphin can contribute to central sensitization and pain amplification, sometimes through non-opioid mechanisms involving NMDA receptor activation.

Dynorphin A is also involved in stress responses. Its release is stimulated by corticotropin-releasing factor (CRF) and stress exposure, and it mediates some of the negative emotional consequences of stress. The dynorphin/KOR system has become a significant target for drug development, with KOR antagonists being investigated for depression, anxiety, addiction, and chronic pain conditions. The KOR antagonist aticaprant has shown promise in clinical trials for major depressive disorder.